4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | $1.28 | $1.29 | +0.4% | Beat |
| Q3 2026 | 2025-12-31 | $1.26 | $1.31 | +3.7% | Beat |
| Q2 2026 | 2025-09-30 | $1.12 | $1.27 | +13.3% | Beat |
| Q1 2026 | 2025-06-30 | $1.03 | $1.10 | +7.2% | Beat |
Earnings Beat Rate
Haemonetics has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →